BACKGROUND: Approximately half of all patients with tumors need radiotherapy. Long-term survivors may suffer from late sequelae of the treatment. The existing radiotherapeutic techniques are being refined so that radiation can be applied more precisely, with the goal of limiting the radiation exposure of normal tissue and reducing late sequelae. METHODS: This review is based on the findings of a selective search in PubMed for publications on late sequelae of conventional percutaneous radiotherapy, January 2000 to May 2020. Late sequelae affecting the central nervous system, lungs, and heart and the development of second tumors are presented, and radiobiological mechanisms and the relevant technical and conceptual considerations are discussed. RESULTS: The current standard of treatment involves the use of linear accelerators, intensity-modulated radiotherapy (IMRT), image-guided and respiratory-gated radiotherapy, and the integration of positron emission tomography combined with computed tomography (PET-CT) in radiation treatment planning. Cardiotoxicity has been reduced with regard to the risk of coronary heart disease after radiotherapy for Hodgkin's lymphoma (hazard ratio [HR] 0.44 [0.23; 0.85]). It was also found that the rate of radiation- induced pneumonitis dropped from 7.9% with conformal treatment to 3.5% with IMRT in a phase III lung cancer trial. It is hoped that neurocognitive functional impairment will be reduced by hippocampal avoidance in modern treatment planning: an initial phase III trial yielded a hazard ratio of 0.74 [0.58; 0.94]. It is estimated that 8% of second solid tumors in adults are induced by radiotherapy (3 additional tumors per 1000 patients at 10 years). CONCLUSION: Special challenges for research in this field arise from the long latency of radiation sequelae and the need for largescale, well-documented patient collectives in order to discern dose-effect relationships, and take account of cofactors, when the overall number of events is small. It is hoped that further technical and conceptual advances will be made in the areas of adaptive radiotherapy, proton and heavy-ion therapy, and personalized therapy.
BACKGROUND: Approximately half of all patients with tumors need radiotherapy. Long-term survivors may suffer from late sequelae of the treatment. The existing radiotherapeutic techniques are being refined so that radiation can be applied more precisely, with the goal of limiting the radiation exposure of normal tissue and reducing late sequelae. METHODS: This review is based on the findings of a selective search in PubMed for publications on late sequelae of conventional percutaneous radiotherapy, January 2000 to May 2020. Late sequelae affecting the central nervous system, lungs, and heart and the development of second tumors are presented, and radiobiological mechanisms and the relevant technical and conceptual considerations are discussed. RESULTS: The current standard of treatment involves the use of linear accelerators, intensity-modulated radiotherapy (IMRT), image-guided and respiratory-gated radiotherapy, and the integration of positron emission tomography combined with computed tomography (PET-CT) in radiation treatment planning. Cardiotoxicity has been reduced with regard to the risk of coronary heart disease after radiotherapy for Hodgkin's lymphoma (hazard ratio [HR] 0.44 [0.23; 0.85]). It was also found that the rate of radiation- induced pneumonitis dropped from 7.9% with conformal treatment to 3.5% with IMRT in a phase III lung cancer trial. It is hoped that neurocognitive functional impairment will be reduced by hippocampal avoidance in modern treatment planning: an initial phase III trial yielded a hazard ratio of 0.74 [0.58; 0.94]. It is estimated that 8% of second solid tumors in adults are induced by radiotherapy (3 additional tumors per 1000 patients at 10 years). CONCLUSION: Special challenges for research in this field arise from the long latency of radiation sequelae and the need for largescale, well-documented patient collectives in order to discern dose-effect relationships, and take account of cofactors, when the overall number of events is small. It is hoped that further technical and conceptual advances will be made in the areas of adaptive radiotherapy, proton and heavy-ion therapy, and personalized therapy.
Authors: Aliki J Taylor; Mark P Little; David L Winter; Elaine Sugden; David W Ellison; Charles A Stiller; Marilyn Stovall; Clare Frobisher; Emma R Lancashire; Raoul C Reulen; Michael M Hawkins Journal: J Clin Oncol Date: 2010-11-15 Impact factor: 44.544
Authors: Linda Douw; Martin Klein; Selene Saa Fagel; Josje van den Heuvel; Martin Jb Taphoorn; Neil K Aaronson; Tjeerd J Postma; W Peter Vandertop; Jacob J Mooij; Rudolf H Boerman; Guus N Beute; Jasper D Sluimer; Ben J Slotman; Jaap C Reijneveld; Jan J Heimans Journal: Lancet Neurol Date: 2009-08-07 Impact factor: 44.182
Authors: Chelsea C Pinnix; Grace L Smith; Sarah Milgrom; Eleanor M Osborne; Jay P Reddy; Mani Akhtari; Valerie Reed; Isidora Arzu; Pamela K Allen; Christine F Wogan; Michele A Fanale; Yasuhiro Oki; Francesco Turturro; Jorge Romaguera; Luis Fayad; Nathan Fowler; Jason Westin; Loretta Nastoupil; Fredrick B Hagemeister; M Alma Rodriguez; Sairah Ahmed; Yago Nieto; Bouthaina Dabaja Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-01 Impact factor: 7.038
Authors: Judit Boda-Heggemann; Antje-Christin Knopf; Anna Simeonova-Chergou; Hansjörg Wertz; Florian Stieler; Anika Jahnke; Lennart Jahnke; Jens Fleckenstein; Lena Vogel; Anna Arns; Manuel Blessing; Frederik Wenz; Frank Lohr Journal: Int J Radiat Oncol Biol Phys Date: 2015-12-17 Impact factor: 7.038
Authors: Lois B Travis; Wendy Demark Wahnefried; James M Allan; Marie E Wood; Andrea K Ng Journal: Nat Rev Clin Oncol Date: 2013-03-26 Impact factor: 66.675
Authors: Hekun Jin; Susan L Tucker; Hui Helen Liu; Xiong Wei; Sue Sun Yom; Shulian Wang; Ritsuko Komaki; Yuhchyau Chen; Mary K Martel; Radhe Mohan; James D Cox; Zhongxing Liao Journal: Radiother Oncol Date: 2008-10-18 Impact factor: 6.280
Authors: David Azria; Ariane Lapierre; Sophie Gourgou; Dirk De Ruysscher; Jacques Colinge; Philippe Lambin; Muriel Brengues; Tim Ward; Søren M Bentzen; Hubert Thierens; Tiziana Rancati; Christopher J Talbot; Ana Vega; Sarah L Kerns; Christian Nicolaj Andreassen; Jenny Chang-Claude; Catharine M L West; Corey M Gill; Barry S Rosenstein Journal: Front Oncol Date: 2017-04-27 Impact factor: 6.244
Authors: Christopher J D Wallis; Alyson L Mahar; Richard Choo; Sender Herschorn; Ronald T Kodama; Prakesh S Shah; Cyril Danjoux; Steven A Narod; Robert K Nam Journal: BMJ Date: 2016-03-02
Authors: Giorgio Treglia; Barbara Muoio; Gianluca Trevisi; Maria Vittoria Mattoli; Domenico Albano; Francesco Bertagna; Luca Giovanella Journal: Int J Mol Sci Date: 2019-09-20 Impact factor: 5.923
Authors: Michael Oertel; Jonas Martel; Jan-Henrik Mikesch; Sergiu Scobioala; Christian Reicherts; Kai Kröger; Georg Lenz; Matthias Stelljes; Hans Theodor Eich Journal: Cancers (Basel) Date: 2021-11-11 Impact factor: 6.639
Authors: Matthias Mäurer; Lukas Käsmann; Daniel F Fleischmann; Michael Oertel; Danny Jazmati; Daniel Medenwald Journal: Radiat Oncol Date: 2022-02-09 Impact factor: 3.481
Authors: Michael Oertel; Christopher Kittel; Jonas Martel; Jan-Henrik Mikesch; Marco Glashoerster; Matthias Stelljes; Hans Theodor Eich Journal: Cancers (Basel) Date: 2021-06-12 Impact factor: 6.639